Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment

被引:65
作者
Dobosz, Paula [1 ]
Stepien, Maria [2 ,3 ]
Golke, Anna [4 ]
Dzieciatkowski, Tomasz [5 ]
机构
[1] Minist Interior Affairs & Adm Warsaw, Dept Genet & Genom, Cent Clin Hosp, PL-02507 Warsaw, Poland
[2] Med Univ Lublin, Dept Infect Dis, PL-20059 Lublin, Poland
[3] Med Univ Lublin, Dept Sports Med, PL-20059 Lublin, Poland
[4] Warsaw Univ Life Sci, Inst Vet Med, Dept Preclin Sci, PL-02776 Warsaw, Poland
[5] Med Univ Warsaw, Chair & Dept Med Microbiol, PL-02005 Warsaw, Poland
关键词
checkpoint inhibitors; immunotherapy; cancer; tumour microenvironment; immune system; LUNG-CANCER; T-CELLS; PD-1; BLOCKADE; ACQUIRED-RESISTANCE; ANTITUMOR IMMUNITY; CTLA-4; OPEN-LABEL; MECHANISMS; IPILIMUMAB; PATHWAYS;
D O I
10.3390/ijms23052847
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunotherapy is a quickly developing type of treatment and the future of therapy in oncology. This paper is a review of recent findings in the field of immunotherapy with an emphasis on immune checkpoint inhibitors. The challenges that immunotherapy might face in near future, such as primary and acquired resistance and the irAEs, are described in this article, as well as the perspectives such as identification of environmental modifiers of immunity and development of anti-cancer vaccines and combined therapies. There are multiple factors that may be responsible for immunoresistance, such as genomic factors, factors related to the immune system cells or to the cancer microenvironment, factors emerging from the host cells, as well as other factors such as advanced age, biological sex, diet, many hormones, existing comorbidities, and the gut microbiome.
引用
收藏
页数:17
相关论文
共 120 条
[91]   Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) [J].
Schachter, Jacob ;
Ribas, Antoni ;
Long, Georgina V. ;
Arance, Ana ;
Grob, Jean-Jacques ;
Mortier, Laurent ;
Daud, Adil ;
Carlino, Matteo S. ;
McNeil, Catriona ;
Lotem, Michal ;
Larkin, James ;
Lorigan, Paul ;
Neyns, Bart ;
Blank, Christian ;
Petrella, Teresa M. ;
Hamid, Omid ;
Zhou, Honghong ;
Ebbinghaus, Scot ;
Ibrahim, Nageatte ;
Robert, Caroline .
LANCET, 2017, 390 (10105) :1853-1862
[92]   Neoantigens in cancer immunotherapy [J].
Schumacher, Ton N. ;
Schreiber, Robert D. .
SCIENCE, 2015, 348 (6230) :69-74
[93]   T cell anergy [J].
Schwartz, RH .
ANNUAL REVIEW OF IMMUNOLOGY, 2003, 21 :305-334
[94]   Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy [J].
Sharma, Padmanee ;
Hu-Lieskovan, Siwen ;
Wargo, Jennifer A. ;
Ribas, Antoni .
CELL, 2017, 168 (04) :707-723
[95]   Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression [J].
Shevach, Ethan M. .
IMMUNITY, 2009, 30 (05) :636-645
[96]   Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials? [J].
Simmet, V. ;
Eberst, L. ;
Marabelle, A. ;
Cassier, P. A. .
ANNALS OF ONCOLOGY, 2019, 30 (11) :1751-1759
[97]   Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy [J].
Sivan, Ayelet ;
Corrales, Leticia ;
Hubert, Nathaniel ;
Williams, Jason B. ;
Aquino-Michaels, Keston ;
Earley, Zachary M. ;
Benyamin, Franco W. ;
Lei, Yuk Man ;
Jabri, Bana ;
Alegre, Maria-Luisa ;
Chang, Eugene B. ;
Gajewski, Thomas F. .
SCIENCE, 2015, 350 (6264) :1084-1089
[98]   Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer [J].
Sokol, Lena ;
Koelzer, Viktor H. ;
Rau, Tilman T. ;
Karamitopoulou, Eva ;
Zlobec, Inti ;
Lugli, Alessandro .
JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
[99]   Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis [J].
Stagg, John ;
Divisekera, Upulie ;
McLaughlin, Nicole ;
Sharkey, Janelle ;
Pommey, Sandra ;
Denoyer, Delphine ;
Dwyer, Karen M. ;
Smyth, Mark J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (04) :1547-1552
[100]   CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity [J].
Steinbrink, K ;
Graulich, E ;
Kubsch, S ;
Knop, J ;
Enk, AH .
BLOOD, 2002, 99 (07) :2468-2476